Free Trial Free TrialFree Trial

More results...

Filter by Content types
Regulatory data
Regulatory reports
Market reports
News analysis

Alerts LATEST ALERTS

  • Canada Smoking and vaping ban issued on all government property…
  • Sweden Budget Bill presented to Parliament…
  • Iceland Bill reintroduced to bring tobacco under EU-style regulation…
  • United States Registration now open for meeting on PMTA processes…
  • Spain Health ministry launches campaign against smoking…
  • Finland Pouches with over 20 mg nicotine to be banned…
  • Canada Canadian Tobacco and Nicotine Survey 2022 results published…
  • Czech Republic EC notified of planned tax labels for nicotine pouches…
  • Lithuania Anti-smuggling bill postponed to await WHO evaluation…
  • Netherlands Government proposes increase in tax on tobacco products…
  • Italy List of heated tobacco prices and duties updated…
  • United States CTP seeks nominations for a new science committee member…
View all
News analysis

Reynolds asks FDA to give Camel Snus products ‘modified risk’ status

Written by || 19th December 2017 || News analysis | IQOS | Snus | North America United States

The US Food and Drug Administration (FDA) will have to consider again next year the possibility that snus could be a reduced-risk form of tobacco, following a series of applications from R.J. Reynolds Tobacco Company ...

Benefits of subscription plans:

  • Stay informed of any legal and market change in the sector that impacts your organization
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

Need help?

Contact a sales representative right now and don’t wait

Email us

Related contents

How Swedish Match snus finally got its FDA modified risk approval
A world of regulation: where the bans are on harm reduction products
PMTA and MRTP: navigating the path to FDA approval for reduced-risk products

Sign up to our newsletter

Stay up-to-date with key market trends and regulatory news and receive complimentary data on a regular basis


    See more


    By signing up you agree to our Privacy Policy. 

    © 2023 Tamarind Media Limited (T/A TobaccoIntelligence)

    TobaccoIntelligence does not provide legal, strategic or investment advice. Tamarind Media Limited, the publisher of TobaccoIntelligence, does not accept any liability or responsibility for information or views published.